Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Date:11/8/2007

Genasense Plus Temodar(R) and Abraxane(R) Show Promising Early Clinical

Activity

BERKELEY HEIGHTS, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced the presentation of clinical data using the Company's lead oncology drug, Genasense(R) (oblimersen sodium) Injection in combination with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound; Abraxis BioScience, Inc.) and Temodar(R) (temozolomide; Schering Plough, Inc.) in patients with advanced metastatic melanoma. The study represents the rapid translation of preclinical results that demonstrated marked anticancer synergy with this drug combination. The results will be presented by Dr. Anna C. Pavlick, New York University School of Medicine, at the Chemotherapy Foundation Symposium XXV, entitled "Innovative Cancer Therapy for Tomorrow", at the Marriott Hotel, New York, NY on November 9, 2007.

To date, 8 patients have been accrued to this trial. Of the first 7 evaluable patients, 5 patients have demonstrated clinical benefit, including 3 partial responses that occurred after the first treatment cycle, which have lasted for 40, 24 and 16 weeks, respectively. Two other patients have maintained stable disease lasting for a minimum of 24 weeks. Two patients had progressive disease, and one patient is too early to evaluate. There have been no episodes of Grade 4 (i.e., life-threatening) side-effects. Four patients experienced Grade 3 leukopenia (i.e., reduction in white blood cell count), and 1 patient had Grade 3 thrombocytopenia (i.e., reduction in platelet count).

"Our goal with this trial is to evaluate the synergy of Genasense with drugs other t
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... VANCOUVER , May 21, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... an upcoming poster presentation at the International Society ... treatment for chronic Achilles tendinosis currently in a ... on May 29 th from 5:30 PM ...
(Date:5/20/2015)... 2015 This year has been one ... US Patented Pearl’s Premium Ultra Low Maintenance Lawn ... country that are coming out of record bad weather. ... of major global concerns related to water, health, and ... the alternative to the standard, water-wasting, chemical-treated standard lawn. ...
(Date:5/20/2015)... Agricultural firm H.J. Baker & Bro., ... of Tiger-Sul. Since the purchase of Tiger Industries ... May 2005, H.J. Baker has leveraged the innovation of ... comprehensive portfolio of product offerings and solutions expertise. The ... the innovation of Tiger-Sul, transforming the company into a ...
(Date:5/20/2015)... May 19, 2015 Research and Markets ... of the "Bone Morphogenetic Proteins Market (Types ... Reconstructive and Oral - Maxillofacial) - Global Industry ... - 2022" report to their offering. ... studied based on the types of recombinant BMPs, ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... Manufacturing, looks at the sustainability performance of 17 ... It has been published by researchers from Queen,s ... researchers from the Euromed Management School Marseille, and ... (IZT) in Berlin. The report details how ...
... wrought when freezing rain collects on roads, power lines, and ... of Pittsburgh-led team demonstrates in the Nov. 3 edition of ... of Di Gao, a chemical and petroleum engineering professor in ... ice on solid surfaces and can be easily applied. ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced ... healthcare investment conferences. , Vincent Milano, president and ... Oppenheimer 20th Annual Healthcare Conference at 4:30 P.M. EST ... being held at the Waldorf=Astoria in New York City. ...
Cached Biology Technology:North America automobile sector bottom of 'world sustainability league' 2North America automobile sector bottom of 'world sustainability league' 3Pitt-led researchers create nanoparticle coating to prevent freezing rain buildup 2ViroPharma to Present at Three November Healthcare Conferences 2
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... weapons used by our immune system to absorb and ... defence mechanism and even multiply within the macrophages. Cell ... a strategy in a recently publication in the journal ... findings reveal that the pathogens escape the 'stomach' of ...
... scientists from Johns Hopkins' Institute for Cell Engineering have discovered ... existing operations. , For more than a century, scientists thought ... them, but in fact, new neurons do form during adulthood ... of the adult brain in mice at the very least. ...
... pharmaceutical potential in a species of red seaweed that ... of Fiji in the south Pacific Ocean. , Some ... cancer cells, bacteria and the HIV virus, according to ... two of them exhibit anti-bacterial activity towards antibiotic-resistant Staphylococcus ...
Cached Biology News:Dangerous tricksters: Some bacterie use immune cells to reproduce 2Dangerous tricksters: Some bacterie use immune cells to reproduce 3New neurons take baby steps in the adult brain 2Seaweed yields new compounds with pharmaceutical potential 2Seaweed yields new compounds with pharmaceutical potential 3Seaweed yields new compounds with pharmaceutical potential 4
... PTC-100 thermal cycler holds 96 x 0.2 ... Bonnet heated lid incorporates a thumbwheel to ... PCR vessels for oil-free cycling. Peltier heat ... calibration and ramping rates of up to ...
... Super Sensitive MultiLink IHC Detection ... secondary antibodies, labeled with multiple ... the bound primary antibody, and ... Streptavidin-Enzyme conjugate. This kit is ...
... performance on minimum space. Thanks to a ... and cooling rates have been achieved that, ... maximum capacity of 48 x 0.2ml tubes, ... much more expensive 96 well instruments. Alternatively, ...
Sf21 Insect Cells (Live) in Max-XP Medium...
Biology Products: